| Autor: |
Ursula Zimber-Strobl, Klaus Rajewsky, Jürgen Ruland, Uta Ferch, Cornelia Hömig-Hölzel, Franziska Jagdhuber, Kristina Djermanovic, Samantha Feicht, Lothar J. Strobl, Samantha Frankenberger, Caroline Hojer |
| Rok vydání: |
2023 |
| Popis: |
PDF file - 364K, Suppl. Figure 1. BM B cell development is comparable in LMP1/CD40//CD19+/- and LMP1/CD40//CD19-/- mice. Suppl. Figure 2. CD40 employs CD19 to mediate survival signals. Suppl. Figure 3. Loss of CD19 abrogates lymphoma development in LMP1/CD40 mice. Suppl. Figure 4A. Stimulation of B cells with anti-IgM in the presence of Dasatinib. Suppl. Figure 4B. Titration of the PI3K inhibitor LY294004 Suppl. Figure 5A. Sorafenib does not affect Erk phosphorylation in LMP1/CD40+ B cells. Suppl. Figure 5B. CD19 expression on different DLBCL and HL cell lines. Suppl. Figure 6A. CD40 expression in different DLBCL cell lines. Suppl. Figure 6B. CD19 phosphorylation after stimulation with a CD40 ligand. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
